The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in .sup.18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in .sup.18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators.

##STR00001##

Disclosed is a composition including flocoumafen and an amount of a configurational stereoisomer of flocoumafen, named enantiomer E.sub.4, such that the ratio of this amount to the amount of flocoumafen in the composition is less than 10%, the enantiomer E.sub.4 being present with the exclusion of a racemic mixture, the enantiomer E.sub.4 having, by chromatographic analysis of flocoumafen, a retention time t.sub.4 having a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.1, t.sub.2 and t.sub.3 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.4, the chromatographic analysis being performed at a temperature of 23.5 C.

Disclosed is a composition including flocoumafen and an amount of a configurational stereoisomer of flocoumafen, named enantiomer E.sub.4, such that the ratio of this amount to the amount of flocoumafen in the composition is less than 10%, the enantiomer E.sub.4 being present with the exclusion of a racemic mixture, the enantiomer E.sub.4 having, by chromatographic analysis of flocoumafen, a retention time t.sub.4 having a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.1, t.sub.2 and t.sub.3 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.4, the chromatographic analysis being performed at a temperature of 23.5 C.

Described are novel derivatives of pogostone and methods of using the same.

Described are novel derivatives of pogostone and methods of using the same.

The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in .sup.18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in .sup.18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in .sup.18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.